Boehringer Ingelheim and Carelon Research have conducted the first large-scale U.S. validation of a new AI-driven tool for chronic kidney disease (CKD) The Klinrisk model predicted disease progression in over 80% of individuals at all stages of the disease, based on data from a diverse…